Review: nonalcoholic steatohepatitis

Area of Science:

• Hepatology
• Gastroenterology
• Internal Medicine

Background:

• Nonalcoholic steatohepatitis (NASH) is a liver condition associated with obesity, diabetes mellitus, hyperlipidemia, and hyperglycemia.
• While often linked to female gender, obesity, and diabetes, these associations may not be absolute, and an underlying cause is not always identifiable.
• The natural history of NASH is not fully understood, with a spectrum of presentations from non-progressive fatty liver to severe steatohepatitis with hepatic necrosis.

Purpose of the Study:

• To review the clinicopathological entity of Nonalcoholic steatohepatitis (NASH).
• To discuss the spectrum of disease progression and clinical significance.
• To outline current and potential treatment strategies for NASH.

Main Methods:

• Literature review of Nonalcoholic steatohepatitis (NASH).
• Analysis of clinicopathological features and disease progression.
• Evaluation of current treatment modalities and ongoing research.

Main Results:

• NASH encompasses a range of liver conditions, from simple fatty liver to progressive fibrosis and cirrhosis.
• The slowly progressive form of NASH is common, potentially leading to cirrhosis and hepatocellular carcinoma (HCC).
• Subfulminant NASH is rare due to increased awareness of risks associated with rapid weight loss.

Conclusions:

• Gradual weight loss is the primary recommended therapy for obese patients with NASH, though adherence is challenging.
• Management includes avoiding precipitous weight loss and controlling diabetes mellitus.
• Treatment for advanced NASH cirrhosis is similar to other cirrhosis types, including liver transplantation; UDCA is under investigation.